Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin as Metformin Add-on in a Korean Population with Type 2 Diabetes.

ABSTRACT:

Introduction

Glucagon-like peptide-1 receptor agonists are well-established type 2 diabetes (T2D) treatments. As variations among populations and culture might influence treatment effects, this post hoc analysis evaluates the efficacy and safety of once-weekly (OW) semaglutide in a Korean population.

Methods

Korean adults with T2D inadequately controlled on metformin included in a 30-week, phase 3a, international, multicentre trial (NCT03061214) compared OW subcutaneous semaglutide (0.5 mg and 1.0 mg) with once-daily sitagliptin (100 mg). Key endpoints included change in glycated haemoglobin (HbA_1c) and body weight; additional endpoints assessed proportions of participants reaching targets of HbA_1c < 7.0% and ≤ 6.5%, ≥ 5% weight loss, and a composite en

SUBMITTER: Lee BW 

PROVIDER: S-EPMC10838861 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature